Skip to content

Dossier · IPX · Dormant

IPX · IperionX Limited · Stock research

Last analysed ·

Current thesis

US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue, below all moving averages, with an open securities probe a downtrend that capitulated into its own discounted raise. Stand aside until it bases and reclaims the low-$30s on volume.

Invalidation trigger

A weekly close below $21.66 loses the 52-week low and the July $21.98 raise floor, confirming the sovereignty bid has exited; secondarily, escalation of the open securities probe to a filed class action, or a second discounted equity raise.

Thesis status

Invalidated resolved published trigger fired How this is scored →

Latest analysis and events for IPX —

As of 2026-07-18, orbyd's latest analysis for IperionX Limited (IPX): US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue, below all moving averages, with an open securities probe a downtrend that capitulated into its own discounted raise. Stand aside until it bases and reclaims the low-$30s on volume.

Invalidation trigger: A weekly close below $21.66 loses the 52-week low and the July $21.98 raise floor, confirming the sovereignty bid has exited; secondarily, escalation of the open securities probe to a filed class action, or a second discounted equity raise.

Next dated event on file: — catalyst in 4d.

Current Thesis

IperionX is a US critical-minerals sovereignty story domestic titanium metal plus a Tennessee heavy-rare-earth resource whose price structure has fully capitulated. The funding overhang the tape had feared since March was resolved on 2026-07-08 the punishing way: a US$50M ADS raise priced at $21.98, roughly 22% under the ~$28 pre-deal level, resetting the stock to within 6% of its 52-week low. Shares closed $22.94 on 2026-07-17, about 63% below the $61.45 high, below every major moving average, with no near-term momentum. The narrative is intact as a story; the chart is a clean downtrend that has now printed a discounted, distress-timed capital raise at the lows.

Bullish and bearish views on IperionX Limited

The model's bull view on IperionX Limited (IPX), in brief: Fresh defense pull, 2026-07-01: an OSW-SWIB award of up to US$6.6M (US$0.2M scoping, up to US$6.4M for scale-up capex over two years) to produce ballistic-grade titanium plate for submarine and land platforms, plus a US Army Ground Vehicle Systems Center purchase order for… The bear view: The raise came at the lows and at a discount: pricing US$50M at $21.98, ~22% below the pre-deal ~$28, signals the company took what the market would give. Both cases follow in full.

Bull Case

  • Fresh defense pull, 2026-07-01: an OSW-SWIB award of up to US$6.6M (US$0.2M scoping, up to US$6.4M for scale-up capex over two years) to produce ballistic-grade titanium plate for submarine and land platforms, plus a US Army Ground Vehicle Systems Center purchase order for prototype JLTV titanium fasteners immaterial in dollars, but a qualification foothold.
  • Titan DFS economics, 2026-06-04: US$813M after-tax NPV8, 39.4% IRR, US$1.9B after-tax free cash flow, ~US$2.8B LOM EBITDA over a 14-year reserve-covered mine, US$381.3M development capex, 3.6-year payback, with a Dy/Tb/Y heavy-rare-earth concentrate a single domestic source of the elements China restricts.
  • Land consolidation, 2026-06-15: agreement to acquire Covia's Camden silica-sand assets for US$3M ~2,800 acres in the same McNairy mineral-sand system as Titan, adding feedstock optionality.
  • Sell-side has not marked down: BTIG reiterated Buy with a $55 target on 2026-06-05; consensus sits ~$54 (5 buy / 0 sell) against a $22.94 spot a ~2.4x gap that is either deep value or a stale cluster overdue for cuts.
  • Macro template is live: MP Materials' 2026 DoD partnership set a US$110/kg NdPr floor plus a government equity stake, and a US$2.5B Strategic Resilience Reserve bill was introduced January 2026 a precedent Titan's Dy/Tb concentrate could fit.

Bear Case

  • The raise came at the lows and at a discount: pricing US$50M at $21.98, ~22% below the pre-deal ~$28, signals the company took what the market would give. The stock fell ~4.3% after-hours on the 2026-07-08 print and has traded at or near the offer since.
  • Still pre-revenue, still burning: ~US$16.3M/qtr operating outflow; first customer revenue only guided to commence and scale across H2 CY2026, with Virginia HAMR powder around 4.2 t in March (~50 tpa annualized) against a ~200 tpa end-CY2026 target. Titan's 1,400 tpa titanium metal is a mid-2027+ event needing project financing well beyond this raise.
  • Structure has broken down: the $22.94 close sits ~63% below the $61.45 high, gave back the entire post-DFS advance and the early-July bounce to ~$28–29, and holds a sequence of lower highs and lower lows into the $21.66 52-week low. Price is below every major moving average.
  • Open securities investigation: multiple firms (Glancy Prongay, Holzer & Holzer, Frank R. Cruz) have circled since March 2026 over the Right-of-use restatement a June-30-2025 carrying amount corrected from $21,445,038 to $3,752,600, disclosed as a "typographic error" on 2026-03-13, after which the stock fell ~16% intraday and later to $29.44 on 2026-03-16. A filed class action would deepen the discount.
  • No scheduled re-rating catalyst: the DFS is spent and the raise is done; the next dated event is a quarterly cash report, not a mine or an offtake.

Setup & Price Structure

Spot $22.94 (2026-07-17 close; $23.39 after-hours) sits ~6% above the $21.66 52-week low and the $21.98 raise clearing price, and ~63% below the $61.45 high. The tape has round-tripped the June DFS advance and the early-July bounce to ~$28–29, and now trades below all major moving averages in a lower-high/lower-low downtrend. The July raise concentrates a support shelf at $21.66–$21.98, which now doubles as the institutional cost basis set in the deal; a weekly close under it removes the last floor. For a momentum book this is a stand-aside, not an entry the name sits in averaging-down territory, where "the overhang is cleared, it's cheap now" is the trap that keeps buyers early. Constructive re-engagement needs a base that holds the shelf and a reclaim of the low-$30s on expanding volume, ideally with a scale government catalyst behind it.

Catalyst Calendar (next 30 days)

  • ~2026-07-23 (est.): ASX Appendix 4C June-quarter cash report (the prior-year June quarterly landed 2025-07-23). With funding now answered, the read is the production ramp (HAMR powder tpa), the June-30 cash print versus the US$36–40M guide, and revenue-commencement timing for H2 CY2026.
  • Ongoing, undated: securities investigation open since 2026-03 a lead-plaintiff or class-action filing could land in any session; no fixed date.
  • H2 CY2026 window (not a single date): first customer titanium revenue expected to commence and scale as qualification programs and purchase-order timing firm up.

What Would Change Our Mind

Constructive: a base that holds the $21.66–$21.98 shelf followed by a reclaim of the low-$30s on expanding volume, or an MP-Materials-scale government event a DoD/EXIM/DPA Title III offtake, price-floor, or equity stake on Titan's Dy/Tb concentrate which would re-rate the equity independent of the chart. The 2026-07-01 OSW-SWIB plate award and Army fastener order are incremental steps toward that, short of the event itself. Destructive: a weekly close below $21.66 (loses the 52-week low and the July raise floor), escalation of the securities probe to a filed suit, or a second discounted raise.

Correlation Notes

IPX trades as a US critical-minerals sovereignty proxy alongside MP Materials (the rare-earth DoD price-floor/equity precedent) and, more loosely, domestic titanium and defense-metals names. Dual-listed on the ASX (IPX.AX); the NASDAQ ADR represents 10 ordinary shares each and gaps on overnight Australian moves, so US sessions often digest an ASX gap rather than lead it. Beta to broad indices is low the dominant drivers are idiosyncratic (dilution, the securities probe, government-offtake headlines), with a secondary sensitivity to the rare-earth and critical-minerals policy cycle. Titanium and zircon commodity prices are a slow background input, not a session-to-session driver.

Notes

  • Pre-revenue, ~US$16.3M/qtr operating burn; Mar-31-2026 cash US$48.2M, mgmt guides Jun-30 to US$36-40M → capital raise likely H2 2026, watch for dilution.
  • Securities-fraud investigation (Frank R. Cruz, Howard G. Smith) open since Mar 2026 over a balance-sheet restatement (Right-of-use assets $21.4M→$3.75M); stock fell 27.4% to $29.44 on 2026-03-16.
  • NOT earnings-driven. Cadence is ASX Appendix 4C quarterly cash reports (~late July for June quarter) that's the liquidity/raise tell, not an EPS print.
  • Dual-listed ASX (IPX.AX); NASDAQ ADR gaps on overnight Australian moves.
  • 52-wk range $21.66-$61.45; spot ~$40 = ~35% below high, ~35% above March crash low. Recovery structure, not a fresh ATH breakout.
  • DFS is a study not a built mine Titan needs financing + construction; titanium 1,400 tpa is mid-2027. Long runway to FCF.
  • 2026-06-04 DFS sold the news: -10.3% ASX then -12.58% NASDAQ to $35.22 on 2026-06-05, losing the $36 recovery shelf. Momentum leg broken digestion tape, not accelerating. Re-engage only on a base reclaiming ~$40-42 on volume.
  • Pre-revenue, ~US$16.3M/qtr operating burn; Mar-31-2026 cash US$48.2M, mgmt guides Jun-30 to US$36-40M → capital raise likely H2 2026; dilution is the dominant overhang.
  • Securities-fraud investigation (Frank R. Cruz, Howard G. Smith) open since Mar 2026 over the Right-of-use restatement ($21.4M→$3.75M); stock fell 27.4% to $29.44 on 2026-03-16. Escalation = step aside.
  • NOT earnings-driven. Real cadence is the ASX Appendix 4C quarterly cash report (~late July for the June quarter) that's the liquidity/raise tell. A 2026-06-09 'earnings date' on US data vendors is a likely artifact, not a confirmed print.
  • Re-acceleration catalyst to watch: an MP-Materials-style DoD/EXIM/DPA Title III offtake, price-floor or equity event on Titan's Dy/Tb concentrate. None confirmed; would re-rate the equity if it lands. Reference: MP's US$110/kg NdPr floor + DoD equity stake.
  • Dual-listed ASX (IPX.AX); NASDAQ ADR (IPX) gaps overnight on Australian moves single-day ADR drops can compound the prior ASX session.
  • DFS is a study not a built mine Titan needs project finance + construction; titanium 1,400 tpa is mid-2027. Long runway to FCF.
  • BTIG reiterated Buy, raised PT to $55 on 2026-06-05 into the selloff; consensus ~$55-57 (median ~$53), 5 buy / 0 sell street diverging from a $35 tape.
  • Pre-revenue, ~US$16.3M/qtr operating burn; Mar-31-2026 cash US$48.2M, mgmt guides Jun-30 to US$36-40M (~2-3 quarters runway) → capital raise likely H2 2026; dilution is the dominant overhang.
  • NOT earnings-driven. Real cadence is the ASX Appendix 4C quarterly cash report (~late July for the June quarter, est. ~2026-07-23) that is the liquidity/raise tell, not an EPS print. US data-vendor 'earnings dates' for IPX are likely artifacts.
  • Securities-fraud investigation (Frank R. Cruz, Howard G. Smith) open since March 2026 over the Right-of-use restatement ($21.4M→$3.75M); ADR fell 27.4% to $29.44 on 2026-03-16. SEC inquiry or filed class action = step aside.
  • Structure fully broken June 2026: $45.46 June high → $35.22 DFS-day close (06-05) → failed ~$37 bounce on Camden deal (06-15) → $26.50 close (06-26), ~42% off the high. Below all MAs; first support is the $21.66 52-week low. Falling-knife / value-trap, not a momentum setup.
  • Re-acceleration catalyst to watch: an MP-Materials-style DoD/EXIM/DPA Title III offtake, price-floor or equity event on Titan's Dy/Tb concentrate, or a Titan US$381.3M financing term sheet. None confirmed; either would re-rate the equity. Reference: MP's US$110/kg NdPr floor + DoD equity stake.
  • Dual-listed ASX (IPX.AX) + NASDAQ ADR (IPX); the ADR gaps on overnight Australian moves, so US-session technical levels are noisy.
  • Sell-side lagging price: BTIG PT $55 (2026-06-05), consensus ~$54, 5 buy / 0 sell vs ~$26.50 spot a ~2x gap that has not yet been cut.
  • Titan DFS is a study, not a built mine: US$381.3M capex, multi-year construction, titanium 1,400 tpa not until mid-2027. Long runway to FCF.
  • Pre-revenue; ~US$16.3M/qtr operating burn. June-30 cash guided US$36-40M; Titan mine still needs project financing beyond this raise; not funded to FCF.
  • 2026-07-08 raise: 2,275,000 ADS (22.75M new ordinary shares) at $21.98 = ~US$50M gross; Cantor Fitzgerald sole book-runner, Roth + B. Riley co-managers; closed ~2026-07-09. ~22% discount to the ~$28 pre-deal price, ~7% dilution. Distress-priced at the 52-week lows.
  • Securities investigation open since March 2026 (Glancy Prongay, Holzer & Holzer, Frank R. Cruz) over the Right-of-use restatement: June-30-2025 carrying amount corrected from $21,445,038 to $3,752,600, disclosed as a 'typographic error' 2026-03-13; stock fell ~16% intraday then to $29.44 on 2026-03-16. Still investigation stage a filed class action = step aside.
  • NOT earnings-driven. Cadence is the ASX Appendix 4C quarterly cash report (~2026-07-23 for the June quarter; prior-year June quarterly landed 2025-07-23). Now that the raise answered funding, the tell is production ramp + revenue-commencement timing, not a solvency scare.
  • Dual-listed ASX (IPX.AX); NASDAQ ADR = 10 ordinary shares each, gaps on overnight Australian moves.
  • Re-acceleration catalyst to watch: an MP-Materials-style DoD/EXIM/DPA Title III offtake, price-floor, or equity event on Titan's Dy/Tb heavy-REE concentrate. 2026-07-01 OSW-SWIB US$6.6M titanium-plate award + Army JLTV fastener PO are incremental, not the scale event. Reference: MP's US$110/kg NdPr floor + DoD equity stake.
  • Titan DFS (2026-06-04) is a study, not a built mine: US$813M after-tax NPV8, 39.4% IRR, US$381.3M capex, 3.6-yr payback; titanium 1,400 tpa is a mid-2027+ event with a long runway to FCF.
  • 52-wk range $21.66-$61.45; spot $22.94 (2026-07-17) ≈ 6% above the low, ~63% below the high. Broken downtrend, below all major moving averages.
  • Sell-side stale/unrevised: BTIG Buy PT $55 (2026-06-05); consensus ~$54 (5 buy / 0 sell) vs ~$23 spot ~2.4x gap not yet cut.

Related · shared themes

See also · stocks to watch